BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ArtVentive Medical Group, Inc. Receives CE Mark Certification for the ArtVentive EOS™ Peripheral Vascular Enoluminal Occlusion System


6/3/2013 7:03:06 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ArtVentive Medical Group, Inc. Announces the Receipt of the CE Mark Certification

CARLSBAD, Calif.--(BUSINESS WIRE)-- ArtVentive Medical Group, Inc. (OTC Bulletin Board: AVTD) announced today that the Company has received its European CE Mark certification for the ArtVentive EOS™ Peripheral Vascular Enoluminal Occlusion system.

“This is a very significant achievement in the Company’s history as it moves toward commercialization and its planned launch into the European markets,” stated Dr. Leon Rudakov, President and CTO. “The CE Mark also paves the way to facilitate approvals for the ArtVentive EOS™ device internationally in meeting with the Company’s global mandate,” stated Jim Graham, CEO and Chairman.

About ArtVentive Medical Group, Inc.

ArtVentive Medical Group, Inc., with its corporate headquarters in Carlsbad, California, is an innovative, multi-faceted medical device corporation committed to developing, manufacturing and marketing a family of endoluminal occlusion devices (EOS).

The ArtVentive EOS™ system encompasses strategically innovative cutting edge devices that are unique, internationally patented and trademarked. The EOS device is catheter based and self-expandable serving for permanent or temporary (reversible) occlusion of body lumens (a cavity found within the vascular system and organ network within the body). The revolutionary device is based on a proprietary technology platform and will serve in many cases as a safe and reliable alternative to major surgery. This inventive breakthrough in technology is bringing the current interventional, image guided techniques to a new level of sophistication, resolving significant and unaddressed health issues.

The ArtVentive EOS device targets a substantive multi-billion dollar market demand in several major clinical areas including peripheral, neurovascular, women’s health (minimally invasive contraceptive device), interventional cardiology and pulmonary health issues.

More information about the Company can be found at www.artventivemedical.com.

Forward-Looking Statements

This news release may include "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements are based on the beliefs by our management as well as assumptions made by and information currently available to the company. These statements reflect the company's current views with respect to future events and are not guarantees of future performance. These statements may involve risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the said forward-looking statements. These factors include, among other things, the company's periodic reports filed with the Securities and Exchange Commission. You should not put undue reliance on any forward-looking statements. Except as required by law, the company does not undertake any obligation to update or revise these forward-looking statements to reflect new information or events or circumstances that occur after the date of this news release or to reflect the occurrence of unanticipated events or otherwise. Readers are advised to review the company's filings with the Securities and Exchange Commission which are available from the SEC's EDGAR database at www.sec.gov, at various SEC reference facilities in the United States.

Contact:

ArtVentive Medical Group, Inc.

H.J. (Jim) Graham, CEO

760-471-7700

hjgraham@artventivemedical.com



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES